Skip to contentpdufa.bio

buntanetap DUET-AD (Phase 3)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

buntanetap DUET-AD (Phase 3) is an Annovis Bio, Inc. program in early Alzheimer's disease. Its next catalyst is a Readout in Mar 2027.

ANVS catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: early Alzheimer's disease. Sponsor: Annovis Bio, Inc. (ANVS). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Mar 2027ANVS

Questions

When is buntanetap DUET-AD (Phase 3)'s next FDA decision or readout?

The next tracked catalyst for buntanetap DUET-AD (Phase 3) is a Readout in Mar 2027.

What happened at buntanetap DUET-AD (Phase 3)'s most recent FDA decision?

No FDA decision for buntanetap DUET-AD (Phase 3) is in our archive yet.

What is buntanetap DUET-AD (Phase 3) used for?

In our records buntanetap DUET-AD (Phase 3) is under review or in development for early Alzheimer's disease.

Who makes buntanetap DUET-AD (Phase 3)?

Annovis Bio, Inc. (ANVS).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.